Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cannabidiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 5/20 | 1.00 |
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE9A | O76083 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cannabidiol SCHEMBL16224872 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL119679 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL122259 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL23934764 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL2229837 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL23460334 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL20201772 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL2799993 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL20930113 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL16212393 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023130139-A2 | USE OF CANNABINOID COMPOUNDS IN THE TREATMENT OF SKIN DAMAGE AND SKIN DISORDERS | BRYANT CYNTHIA W (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2023130142-A2 | COMPOSITIONS AND METHODS USING CANNABINOID COMPOUNDS FOR TREATING URINARY TRACT DISORDERS | BRYANT CYNTHIA W (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2023092079-A1 | USE OF CANNABINOID COMPOUNDS TO TREAT GASTROINTESTINAL DISORDERS | BRYANT CYNTHIA W (US) | 2023-05-25 | — | — | WO | claimed |
| US-20230037975-A1 | USE OF CANNABINOID COMPOUNDS IN ORAL CARE COMPOSITIONS TO INHIBIT THE GROWTH OF P. GINGIVALIS | DEMETRIX, INC. | 2023-02-09 | — | — | US | claimed |
| WO-2023009877-A1 | USE OF CANNABINOID COMPOUNDS IN ORAL CARE COMPOSITIONS TO INHIBIT THE GROWTH OF P. GINGIVALIS | DEMETRIX, INC. (US) | 2023-02-02 | — | — | WO | claimed |
| WO-2023278768-A1 | ALLEVIATION OF ITCHING SENSATIONS USING CANNABINOID COMPOUNDS | DEMETRIX, INC. (US) | 2023-01-05 | — | — | WO | claimed |
| US-20230000936-A1 | ALLEVIATION OF ITCHING SENSATIONS USING CANNABINOID COMPOUNDS | DEMETRIX, INC. | 2023-01-05 | — | — | US | claimed |
| US-20220401407-A1 | REGULATION OF THE SLEEP/WAKE CYCLE USING CANNABINOID COMPOUNDS | DEMETRIX, INC. | 2022-12-22 | — | — | US | claimed |
| WO-2022261662-A1 | REGULATION OF THE SLEEP/WAKE CYCLE USING CANNABINOID COMPOUNDS | DEMETRIX, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| US-20220304911-A1 | ORAL CARE PRODUCT WITH CANNABINOID COMPOUNDS | DEMETRIX, INC. | 2022-09-29 | — | — | US | claimed |
| WO-2022204731-A1 | ORAL CARE PRODUCT WITH CANNABINOID COMPOUNDS | DEMETRIX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| EP-4620940-A2 | SYNTHESIS OF (+)-CANNABINOIDS AND THEIR THERAPEUTIC EFFECTS | Symrise AG (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-12324789-B2 | Method to treat psoriasis | APIRX PHARMACEUTICAL USA, LLC (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250090556-A1 | Polycannabinoid Compositions and Uses Thereof | Ommio Health, Inc. | 2025-03-20 | — | — | US | disclosed |
| US-8383842-B2 | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol | PURDUE PHARMA L.P. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110097283-A1 | CHEWING GUM COMPOSITIONS COMPRISING CANNABINOIDS | MAREDA HOLDING BV | 2011-04-28 | — | — | US | disclosed |
| US-20090298930-A1 | Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol | EURO-CELTIQUE S.A. (LU) | 2009-12-03 | — | — | US | disclosed |
| US-20070072939-A1 | Cannabinoid active pharmaceutical ingredient for improved dosage forms | EURO-CELTIQUE, S.A. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298930-A1 | Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol | CNR2, OPRD1, CNR1 | CNR1 3/4885CNR2 1/4885OPRM1 7/4885 |
| US-20070072939-A1 | Cannabinoid active pharmaceutical ingredient for improved dosage forms | CNR2, CNR1, OPRD1 | CNR1 2/4885CNR2 1/4885OPRM1 10/4885 |
| US-12324789-B2 | Method to treat psoriasis | CNR2, CNR1, FAAH2 | CNR1 2/4885CNR2 1/4885OPRM1 1962/4885 |
| US-20250090556-A1 | Polycannabinoid Compositions and Uses Thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885OPRM1 29/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | CNR1 106/4885CNR2 91/4885OPRM1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.